Genetic Variants May Reduce GLP-1 Medication Effectiveness In 10% Of People With Type 2 Diabetes

About 10% of people carry genetic variants associated with reduced effectiveness of glucagon-like peptide-1 (GLP-1) medications for type 2 diabetes, according to a recent study. GLP-1 medications are used to treat type 2 diabetes and obesity.

Only about half of people with type 2 diabetes achieve the recommended target HbA1c level of 7% or lower. Among people with the genetic variants associated with reduced GLP-1 response, only 11.5% achieved an HbA1c level below 7%, compared to 25.3% of those without the variants. The researchers reported no differences in response to other type 2 . . .